Explore

Moderna shares surge as Merck-partnered melanoma vaccine cuts recurrence in large trial

Moderna shares surge as Merck-partnered melanoma vaccine cuts recurrence in large trial

By Julie Steenhuysen and Michael Erman CHICAGO, Aug 19 (Reuters) - Moderna's personalized mRNA cancer therapy, developed with Merck, reduced the risk of recurrence and spread of skin cancer in a late-stage trial when combined with immunotherapy drug Keytruda, sending Moderna's shares up around 150%

Moderna surges as Merck-partnered melanoma vaccine cuts recurrence in large trial

Moderna surges as Merck-partnered melanoma vaccine cuts recurrence in large trial

By Julie Steenhuysen and Christy Santhosh CHICAGO, Aug 19 (Reuters) - Moderna's personalized mRNA cancer therapy, developed with Merck, reduced the risk of melanoma recurrence and spread in a late-stage trial when combined with Keytruda, sending the biotech's shares surging 90% in premarket trading.

Wall St set for higher open after retail earnings; Moderna soars

Wall St set for higher open after retail earnings; Moderna soars

By Avinash P and Purvi Agarwal Aug 19 (Reuters) - The main U.S. stock indexes were on track to open higher on Wednesday after a tech-led selloff in the previous session as investors assessed fresh retailer results, while Moderna's shares skyrocketed following successful vaccine trial results.

Moderna shares double as cancer vaccine data rekindles investor hopes

Moderna shares double as cancer vaccine data rekindles investor hopes

By Christy Santhosh and Shashwat Chauhan Aug 19 (Reuters) - Moderna shares more than doubled on Wednesday, adding about $30 billion to its market value, after promising late-stage data on its personalized mRNA cancer therapy developed with Merck sent investors piling into the stock.

Wall St up after tech selloff as yields retreat; Moderna surges

Wall St up after tech selloff as yields retreat; Moderna surges

By Avinash P and Purvi Agarwal Aug 19 (Reuters) - The main U.S. stock indexes recovered on Wednesday after a technology-driven slump in the previous session as government bond yields retreated from multi-decade highs and investors assessed a slew of corporate updates.

US kindergarten vaccine coverage continues downward trend, falling 0.1%

US kindergarten vaccine coverage continues downward trend, falling 0.1%

By Michael Erman and Julie Steenhuysen Aug 17 (Reuters) - U.S. kindergarten vaccination coverage fell 0.1% during the 2025-2026 school year, continuing a downward trend that has seen declines every year except one since the onset of COVID-19, according to data from the U.S.

Gilead yanks out a thorn in its side in major court ruling

Gilead yanks out a thorn in its side in major court ruling

A federal appeals court just handed Gilead Sciences (GILD) a legal win that extends into the company's revenue. The decision blocks a group of companies from importing cheaper foreign versions of Gilead's top HIV drug and selling them to American patients. For a company that relies heavily on a ...

US kindergarten vaccine coverage falls 0.1%, CDC says

US kindergarten vaccine coverage falls 0.1%, CDC says

Aug 17 (Reuters) - U.S. kindergarten vaccination coverage fell 0.1% during the 2025-2026 school year, the U.S. Centers for Disease Control and Prevention said on Monday.

Stocks, dollar fall after weak data; yields rise

Stocks, dollar fall after weak data; yields rise

By Karen Brettell NEW YORK, Aug 17 (Reuters) - U.S. stocks ended down on Monday and the dollar hit a two-month low against the euro as soft U.S. economic data, including an unexpected drop in retail sales, prompted markets to scale back bets on an imminent Federal Reserve interest rate move.

Bond selloff slows but stocks sink

Bond selloff slows but stocks sink

By Tom Westbrook SINGAPORE, Aug 19 (Reuters) - Global bond yields hovered near their highest for decades on Wednesday, as fears over swelling sovereign debt pushed borrowing costs higher and rattled stock markets worldwide.

Moderna shares surge as melanoma vaccine with Merck succeeds in large trial

Moderna shares surge as melanoma vaccine with Merck succeeds in large trial

By Julie Steenhuysen CHICAGO, Aug 19 (Reuters) - Moderna's mRNA vaccine combined with Merck's immunotherapy Keytruda succeeded in a late-stage trial for skin cancer, the companies said on Wednesday, sending shares of the vaccine maker up 60% in premarket trading.

S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq

S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq

By Avinash P and Purvi Agarwal Aug 17 (Reuters) - The S&P 500 was set to open subdued on Monday as markets weighed the prospect of fewer interest-rate hikes against Middle East tensions, while the report of a strong revenue forecast from AI lab Anthropic put the Nasdaq on course for a higher open.